Tuesday brought a flurry of analyst activity across Wall Street, with firms adjusting their outlooks on companies ranging from database software to lithium mining. The moves span multiple sectors and include both upgrades and target adjustments that could signal shifting sentiment in various corners of the market.

Semiconductor and Tech Moves

Keybanc analyst Steve Barger increased the price target for Applied Materials Inc (AMAT) from $240 to $285 while maintaining an Overweight rating. With shares closing Monday at $254.75, the new target implies approximately 12% upside potential. The semiconductor equipment maker continues to attract bullish sentiment as the chip industry navigates through evolving demand patterns.

In another notable tech move, B of A Securities analyst Vivek Arya boosted the price target for Credo Technology Group Holding Ltd (CRDO) from $165 to $240, maintaining a Buy rating. This represents a substantial increase for the connectivity solutions company, whose shares closed at $171.13 on Monday.

Meanwhile, Guggenheim analyst Howard Ma raised Mongodb Inc (MDB) price target from $400 to $450 while keeping a Buy rating. The database platform company's shares closed at $328.87 on Monday, suggesting the new target reflects continued confidence in the company's growth trajectory.

Industrial and Logistics Updates

B of A Securities analyst Ken Hoexter raised the price target for XPO Inc (XPO) from $151 to $158, maintaining a Buy rating. The logistics company's shares closed at $143.43 on Monday, positioning the new target about 10% above current levels.

JP Morgan analyst David Karnovsky increased Formula One Group (FWONK) price target from $120 to $122 while maintaining an Overweight rating. The racing entertainment company's shares closed at $94.80 on Monday, suggesting analysts see continued growth potential in the motorsports business.

Healthcare Sector Adjustments

Barclays analyst Matt Miksic increased Johnson & Johnson (JNJ) price target from $176 to $197 while maintaining an Equal-Weight rating. Interestingly, the healthcare giant's shares settled at $205.34 on Monday, already trading above the new analyst target.

Guggenheim analyst Jason Cassorla raised Universal Health Services Inc (UHS) price target from $253 to $274, maintaining a Buy rating. The hospital operator's shares closed at $239.43 on Monday.

In biotech news, Cantor Fitzgerald analyst Josh Schimmer cut the price target for Janux Therapeutics Inc (JANX) from $200 to $150 while maintaining an Overweight rating. The shares settled at $33.99 on Monday, well below even the reduced target, suggesting analysts still see significant long-term potential despite the haircut.

Materials and Specialty Chemicals

Baird analyst Ben Kallo upgraded Albemarle Corp (ALB) from Underperform to Neutral while raising the price target from $81 to $113. This represents a notable shift in sentiment for the lithium producer, whose shares closed at $128.33 on Monday, already trading above the new target. The upgrade suggests analysts may be warming to the lithium space after a challenging period for the sector.

TD Cowen analyst Jason Gabelman upgraded Darling Ingredients Inc (DAR) from Hold to Buy while raising the price target from $34 to $45. The sustainable ingredients company's shares closed at $36.77 on Monday, giving the new target substantial upside potential of roughly 22%.

These analyst moves reflect the ongoing recalibration happening across markets as firms digest earnings results, industry trends, and macroeconomic signals. Whether these new targets prove prescient remains to be seen, but they offer a window into how Wall Street's research desks are thinking about positioning across different sectors.